However, a number of in vitro studies have convincingly shown AML primary cells to be resistant to the proapoptotic activity of TRAIL used as a single agent, despite the presence and functioning of the TRAIL death pathway. The gene discussed is TNFSF10; the disease is acute myeloid leukemia.